|
Inavolisib Clinical Trials
16 actively recruiting trials across 7 locations
▲ +1 trial since August 2026
Also known as: GDC-0077, GDC-0077, RO7113755, ITOVEBI™, Itovebi, RG6114 +1 more
Pipeline
Phase 1: 1Phase 2: 7Phase 3: 4Phase 1/2: 3
Top Sponsors
- Hoffmann-La Roche12
- MedSIR1
- German Cancer Research Center1
- GBG Forschungs GmbH1
- Alliance Foundation Trials, LLC.1
Indications
- Cancer16
- Breast Cancer12
- Metastatic Breast Cancer3
- Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer1
- Metastatic Castration-resistant Prostate Cancer1
Other5 trials
Duarte, California3 trials
Phase 1/2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
City of Hope - Duarte
Phase 1/2
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
City of Hope Comprehensive Cancer Center
Phase 1/2
Los Angeles, California3 trials
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
VA West Los Angeles Medical Center - (CRS) - NAVREF - PPDS
Phase 2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Los Angeles Cancer Network
Phase 2
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Los Angeles Cancer Network
Phase 2
Birmingham, Alabama1 trial
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
UAB Comprehensive Cancer Center
Phase 1
Gilbert, Arizona1 trial
Goodyear, Arizona1 trial
Anaheim, California1 trial
Greenbrae, California1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.